Centene Corporation (CNC) — ESG & Values Scores

Environment story

Centene Corporation discloses no quantified Scope 1, Scope 2, or Scope 3 direct emissions data in the 10-K filing. No renewable electricity percentage, net-zero target year, or decarbonization infrastructure investments are disclosed. The company acknowledges climate change as an operational risk factor (effects on Medicaid membership, cost trends) but does not articulate environmental sustainability commitments, emissions reduction strategies, or climate governance structures. This represents a material gap in ESG disclosure for a company of this scale. Without verified emissions baselines or credible net-zero targets, a strong Environmental score cannot be justified.

Criticisms on file

No disclosed ESG or sustainability report; absence of climate commitments or emissions targets
Source: CNC 10-K SEC Filing 2025; MD&A and Risk Factors sections contain no environmental performance metrics, net-zero pledges, or decarbonization initiatives.

Disclosed initiatives

Climate Risk Acknowledgment

10-K Risk Factors section identifies climate change effects on member populations and healthcare delivery (e.g., 'effects of climate change' listed as external factor affecting medical cost trends and member behavior).

Acknowledgment only; no quantified mitigation or strategic action disclosed.

Social story

Centene's 10-K provides limited quantitative social performance data. CEO-to-median-worker pay ratio is not disclosed, preventing assessment against the 200:1 threshold. Workforce diversity metrics (gender, race/ethnicity) are absent from the filing. No documented union suppression activities or major strikes within 24 months are reported. Supply-chain labor practices are not addressed. The company emphasizes serving underserved and low-income populations through Medicaid and Medicare products, which reflects a pro-social mission, but governance and transparency around internal workforce equity, executive compensation alignment, and labor relations remain opaque. No material labor controversies or NLRB complaints are evident in the documents provided.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Focus on Underserved Populations

Centene markets itself as 'the nation's largest managed care company focused on underserved populations,' serving 12.5M Medicaid, 5.5M Marketplace, and 1.0M Medicare Advantage members, with emphasis on low-income, complex populations including dual-eligible and D-SNP beneficiaries.

Aligns company mission with social inclusion; serves as primary competitive differentiation in government programs.
Community-Based Care Model

MD&A states 'state-based plans built on community expertise' and 'working hand-in-hand with providers, policymakers, and communities' to 'connect people to essentials like food, housing, utilities, and transportation.'

Positions company as addressing social determinants of health; limited quantitative outcome data disclosed.
Succession Planning and Talent Retention

Risk Factors acknowledge importance of executive succession and workforce retention; company notes it has 'succession plans in place' for executive and senior management team.

Indicates governance structure but no specific retention metrics or diversity targets disclosed.

Governance story

Centene's governance structure exhibits several concerning features. Board independence percentage is not disclosed in the filing, preventing verification against the 75% threshold. No dual-class share structure is indicated; share structure appears standard single-class common stock. Lobbying expenditures are not quantified in the 10-K. However, the company acknowledges extensive regulatory engagement: the Risk Factors section references participation in government procurement protests (Texas, Georgia Medicaid; Pennsylvania, Arizona Medicaid disputes), litigation defense, and regulatory compliance reviews. In Q3 2025, the company recorded a $6.7 billion non-cash goodwill impairment, suggesting asset valuation challenges and potential governance/strategy reassessment. No active lawsuits by shareholders to block climate proposals are documented. The company faces ongoing regulatory audits and compliance reviews from CMS, state insurance departments, and federal agencies across multiple programs, reflecting typical healthcare MCO regulatory intensity but not unique governance failure.

Criticisms on file

$6.7 billion goodwill impairment recorded in Q3 2025 due to market conditions, OBBBA regulatory changes, and stock price decline
Source: CNC 10-K 2025, MD&A section and Note 6; goodwill and intangible assets discussion indicates material revaluation of business units following regulatory and market shifts.
Ongoing Medicaid contract procurement protests and appeals in Texas, Georgia, Pennsylvania, and Arizona with uncertain outcomes
Source: CNC 10-K 2025, MD&A Current and Future Operating Drivers section; company notes it is 'currently protesting the Texas and Georgia Medicaid reprocurements' and litigation continues in Pennsylvania and Arizona.
Regulatory audits and compliance reviews ongoing from CMS on Medicare Star ratings, risk adjustment data validation, encounter data accuracy, and Part D program compliance
Source: CNC 10-K 2025, Risk Factors and MD&A; CMS announced intent to 'accelerate the timing and expand the scope of risk adjustment data validation audits' beginning 2018 audit year forward.

Disclosed initiatives

Regulatory Compliance and Governance Structure

Company maintains compliance with state insurance regulations, federal healthcare laws (HIPAA, False Claims Act, MLR requirements), and CMS Medicare/Medicaid program rules. Board governance includes audit, compensation, and compliance oversight committees (implied by standard corporate governance).

Standard healthcare MCO governance; no competitive differentiation or enhanced governance practices disclosed.
Risk-Based Capital and Financial Solvency Compliance

As of December 31, 2025, regulated subsidiaries maintain $19.7B aggregate statutory capital and surplus against $11.3B minimum requirements; RBC percentage estimated in excess of 350% of Authorized Control Level.

Strong capital adequacy; maintains regulatory compliance and financial stability.
Debt and Capital Management

Company maintains $15.5B senior notes outstanding and $2.0B Term Loan; debt-to-capital ratio of 46.5% at December 31, 2025. Debt repurchase program ($1.0B authorized in 2022; $513M remaining as of December 31, 2025) and stock repurchase program ($1.8B remaining from $10.0B authorization) in place.

Active capital allocation; demonstrates shareholder return focus and financial flexibility.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Centene Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Centene Corporation in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)